Krill oil vs fish oil: which omega-3 absorbs better?

EPA and DHA are the active omega-3s. Whether they come from a sardine, an anchovy or a two-inch Antarctic crustacean, the molecules that do the work in your membranes are the same. What differs between products is the carrier molecule they arrive on — and that carrier is the entire basis of the krill-oil marketing claim. It is worth understanding the three omega-3s — EPA, DHA and DPA — before comparing carriers at all; we cover them in the three omega-3s — EPA, DHA and DPA.

Fish oil comes in three forms. Natural triglycerides (TG) are the form the fish made; the omega-3s sit on a glycerol backbone exactly as they do in food. Re-esterified triglycerides (rTG) are concentrated products that have been put back onto a glycerol backbone after processing. Ethyl esters (EE) are the cheapest concentrated form: during concentration, the fatty acids are transferred onto an ethanol molecule and simply left there.

Krill oil is structurally different. Roughly 30–65% of its EPA and DHA is bound to phospholipids — mainly phosphatidylcholine — with the remainder present as free fatty acids or triglycerides. It also carries astaxanthin, the natural red antioxidant that colours the oil and helps protect it from oxidation, at around 60 mcg per 500 mg capsule, plus a small amount of choline.^[7]

Phospholipids are amphipathic: one end is attracted to water, the other to fat. They emulsify spontaneously. So a phospholipid-bound omega-3 may be handled by the gut more like dietary lecithin than like an oil droplet that has to wait for bile salts and pancreatic lipase. That is a genuinely plausible mechanism for better absorption. The question is how much it matters in a real human being.

Here is the finding that gets lost in the krill-versus-fish argument: the clearest, best-replicated effect of chemical form is not between krill and fish at all. It is inside the fish-oil aisle. Classic bioavailability work comparing marine n-3 formulations ranked the relative uptake of EPA+DHA as re-esterified triglyceride > natural triglyceride > free fatty acid > ethyl ester.^[5] The ethyl ester came last, and not narrowly.

A later critical reexamination of the krill literature summarised earlier estimates of EPA absorption efficiency at roughly 90% for the triglyceride form versus about 60% for the ethyl ester.^[6] Those are ballpark figures rather than precise constants, but the direction is consistent across studies.

The practical point is that the weak link is a cheap ethyl ester product — not fish oil as a category. If you are comparing a bargain-bin EE concentrate against a premium krill oil, you are not testing krill's phospholipid advantage. You are testing the difference between two very different fish-oil qualities and attributing the result to the krill.

There is a real literature here, and it points in both directions. Taken in order, it tells a more useful story than any single trial does.

Ulven and colleagues ran a randomised seven-week comparison in healthy volunteers in which krill oil delivered less EPA+DHA than fish oil — 543 mg/day versus 864 mg/day — yet produced essentially similar changes in plasma fatty acids and blood lipids.^[3] That is the single most quoted result in krill marketing, and the hint it offers is legitimate: more effect per milligram delivered.

Ramprasath and colleagues then found, over four weeks, that krill oil raised the Omega-3 Index — the proportion of EPA and DHA in red blood cell membranes — more than fish oil did.^[4] Against that, Schuchardt's comparative bioavailability study found only a small, non-significant trend toward higher EPA with krill: a nudge, not a decisive win.^[2]

The most rigorous test came from Yurko-Mauro and colleagues, who did what most earlier studies had not: they matched the dose. Sixty-six adults received 1.3 g/day of EPA+DHA for four weeks as fish-oil ethyl ester, fish-oil triglyceride, or krill oil. At four weeks, plasma EPA+DHA was 90.9 µg/mL for the ethyl ester, 108 µg/mL for the triglyceride and 118.5 µg/mL for krill. Krill was numerically highest — but the between-group difference was not statistically significant (p=0.052). The authors' conclusion was parity: broadly comparable plasma levels when the dose is genuinely matched.^[1]

The newest entry complicates that tidy conclusion. A double-blind randomised controlled trial from the Université de Sherbrooke, published in the American Journal of Clinical Nutrition in 2026, gave 72 adults about 1.1 g/day of omega-3 for twelve weeks and found that krill oil produced roughly a 1.5-fold greater increase in plasma EPA and DHA than fish oil at a matched dose. A time-by-sex interaction also emerged: women raised EPA more than men, regardless of which oil they took.^[8]

So where does that leave us? The newest data and some earlier data favour krill modestly. The most tightly dose-matched earlier trial found near-parity. And a critical reexamination of the field argued that many of the early "krill wins" were confounded precisely because the products being compared were not truly dose-matched in the first place.^[6] The net reading is that krill's absorption edge is real but small and inconsistent — not the night-and-day advantage often advertised.

Even granting krill a modest absorption advantage, the arithmetic of dosing works firmly against it. Krill oil is far less concentrated in EPA and DHA than fish oil. A typical 500 mg krill capsule provides only about 90 mg of EPA+DHA. To reach a standard target of 1,000–2,000 mg/day of EPA+DHA you would need six or more krill capsules, against one or two concentrated fish-oil softgels.^[7]

Krill oil also costs more per gram of oil to harvest and process. Stack the two facts together and the cost per gram of actual EPA+DHA — the only unit that matters clinically — is usually several times higher for krill. A 10% or even 50% absorption advantage does not close a three-to-five-fold price gap for most buyers.

If you want to know whether whatever you are taking is actually working, the answer is not on the bottle. It is in your blood: checking your Omega-3 Index after eight to twelve weeks tells you more than any label comparison can.

Krill oil has genuine upsides that have nothing to do with absorption statistics. The capsules are small and easy to swallow. Many people report less fishy reflux and no fishy aftertaste, which is not a trivial consideration for a supplement you are meant to take every day for years. The bundled astaxanthin and choline are small bonuses, and the phospholipid form appeals to people who prefer a food-like delivery.

Fish oil's upsides are less romantic and more decisive: far more EPA+DHA per capsule, a much lower cost per gram of omega-3, and decades of cardiovascular outcome data collected on fish-oil preparations rather than krill.

Safety is broadly similar. Both can cause mild gastrointestinal effects — fishy burp, loose stool — and both carry a theoretical antiplatelet effect at high doses, so caution and a conversation with your physician are warranted if you take anticoagulants or antiplatelet drugs.^[7] One difference is absolute: krill are crustaceans, so krill oil is contraindicated in anyone with a shellfish or crustacean allergy.^[7]